Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease

What Was Tested

This randomized controlled trial paper looks at Somatostatin and Lanreotide in the context of muscle disease (myopathy).

Polycystic liver disease (PCLD) can induce malnutrition owing to extensive hepatomegaly and patients might require liver transplantation.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

Patients also were assessed by the PCLD-specific complaint assessment at these time points.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.

The researchers performed an 18-month prospective study at 2 tertiary medical centers in Belgium from January 2011 through August 2012.

Liver volume and body composition were measured by computed tomography at baseline and at months 6 and 18.

What Was Measured

The subject headings attached to it are Belgium, Cysts, Gastrointestinal Agents, Hepatomegaly, Liver Diseases, Muscles and Peptides, Cyclic.

Author keywords: Clinical Trial, Growth Hormone Deficiency, Health-Related Quality of Life, POLCA, Sarcopenia and Somatostatin Analogues.

What This Means in Plain Language

The paper is a randomized study of Somatostatin and Lanreotide in people with muscle disease (myopathy).

Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association), a journal based in United States.

More context: the Somatostatin compound page and the Lanreotide compound page, Muscle disease (myopathy) research.